Literature DB >> 2493739

Long-term effects of bone marrow transplantation in dogs with mucopolysaccharidosis I.

M A Breider1, R M Shull, G Constantopoulos.   

Abstract

The therapeutic effects of allogeneic bone marrow transplantation (BMT) in a canine model of mucopolysaccharidosis I (MPS I) were investigated. Long-term post-BMT pathologic and biochemical studies were performed on three groups of dogs: 1) MPS I-affected dogs that did not receive BMT, 2) MPS I-affected dogs that received total body irradiation followed by an allogeneic BMT, and 3) normal, unaffected dogs that served as BMT donors. All dogs were necropsied at approximately 20 months after BMT. The severity of MPS I-related lesions in the dogs receiving BMT was greatly diminished. These dogs had only slight cardiac valvular thickening, no meningeal thickening, no renal tubular epithelial vacuolation, decreased neuronal vacuolation, decreased corneal stromal vacuolation, and greatly diminished arterial medial thickening. The severity and incidence of degenerative arthropathy also were decreased in BMT dogs, however, vertebral lesions were similar to nontransplanted, affected dogs. Chondrocytes of both MPS I-BMT and MPS I-no BMT groups had similar marked cytoplasmic vacuolation, except for MPS I-BMT chondrocytes near the articular surface, which had more normal morphology. Ultrastructurally, the liver and kidney tissue in BMT recipients had no appreciable lysosomal accumulation of GAGs. These morphologic findings were supported by near normal levels and electrophoretic patterns of glycosaminoglycans (GAG) in most tissues of BMT recipient dogs. This study demonstrates that BMT is capable of substantially diminishing the severity of MPS I-related lesions in this canine model.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2493739      PMCID: PMC1879520     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  26 in total

1.  Neurochemistry of the mucopolysaccharidoses: brain lipids and lysosomal enzymes in patients with four types of mucopolysaccharidosis and in normal controls.

Authors:  G Constantopoulos; A S Dekaban
Journal:  J Neurochem       Date:  1978-05       Impact factor: 5.372

2.  A rapid and micro method for separation of acidic glycosaminoglycans by two-dimensional electrophoresis.

Authors:  R Hata; Y Nagai
Journal:  Anal Biochem       Date:  1972-02       Impact factor: 3.365

Review 3.  Marrow transplantation for congenital disorders.

Authors:  R J O'Reilly; J Brochstein; R Dinsmore; D Kirkpatrick
Journal:  Semin Hematol       Date:  1984-07       Impact factor: 3.851

Review 4.  Bone marrow transplantation for diseases of childhood.

Authors:  R P Kadota; W A Smithson
Journal:  Mayo Clin Proc       Date:  1984-03       Impact factor: 7.616

5.  Bone marrow transplantation for Niemann-Pick mice.

Authors:  T Sakiyama; M Tsuda; M Owada; K Joh; S Miyawaki; T Kitagawa
Journal:  Biochem Biophys Res Commun       Date:  1983-06-15       Impact factor: 3.575

6.  Bone marrow transplantation in canine mucopolysaccharidosis I. Effects within the central nervous system.

Authors:  R M Shull; N E Hastings; R R Selcer; J B Jones; J R Smith; W C Cullen; G Constantopoulos
Journal:  J Clin Invest       Date:  1987-02       Impact factor: 14.808

7.  Morphologic and biochemical studies of canine mucopolysaccharidosis I.

Authors:  R M Shull; R G Helman; E Spellacy; G Constantopoulos; R J Munger; E F Neufeld
Journal:  Am J Pathol       Date:  1984-03       Impact factor: 4.307

8.  Correction of enzyme deficiency in mice by allogeneic bone marrow transplantation with total lymphoid irradiation.

Authors:  S Slavin; S Yatziv
Journal:  Science       Date:  1980-12-05       Impact factor: 47.728

9.  Induced degradation of glycosaminoglycans in Hurler's and Hunter's syndromes by plasma infusion.

Authors:  N Di Ferrante; B L Nichols; P V Donnelly; G Neri; R Hrgovcic; R K Berglund
Journal:  Proc Natl Acad Sci U S A       Date:  1971-02       Impact factor: 11.205

10.  Long-term neurological effects of bone marrow transplantation in a canine lysosomal storage disease.

Authors:  R M Shull; M A Breider; G C Constantopoulos
Journal:  Pediatr Res       Date:  1988-09       Impact factor: 3.756

View more
  24 in total

1.  Enzyme replacement therapy from birth in a feline model of mucopolysaccharidosis type VI.

Authors:  A C Crawley; K H Niedzielski; E L Isaac; R C Davey; S Byers; J J Hopwood
Journal:  J Clin Invest       Date:  1997-02-15       Impact factor: 14.808

2.  Replacing the enzyme alpha-L-iduronidase at birth ameliorates symptoms in the brain and periphery of dogs with mucopolysaccharidosis type I.

Authors:  Ashley D Dierenfeld; Michael F McEntee; Carole A Vogler; Charles H Vite; Agnes H Chen; Merry Passage; Steven Le; Sahil Shah; Jackie K Jens; Elizabeth M Snella; Karen L Kline; Jennifer D Parkes; Wendy A Ware; Lori E Moran; Amanda J Fales-Williams; Jane A Wengert; R David Whitley; Daniel M Betts; Amy M Boal; Elizabeth A Riedesel; William Gross; N Matthew Ellinwood; Patricia I Dickson
Journal:  Sci Transl Med       Date:  2010-12-01       Impact factor: 17.956

Review 3.  Hurdles in treating Hurler disease: potential routes to achieve a "real" cure.

Authors:  Brigitte T A van den Broek; Jaap van Doorn; Charlotte V Hegeman; Stefan Nierkens; Caroline A Lindemans; Nanda Verhoeven-Duif; Jaap Jan Boelens; Peter M van Hasselt
Journal:  Blood Adv       Date:  2020-06-23

Review 4.  Large animal models of hematopoietic stem cell gene therapy.

Authors:  G D Trobridge; H-P Kiem
Journal:  Gene Ther       Date:  2010-04-29       Impact factor: 5.250

5.  Bone marrow transplantation for mucopolysaccharidosis type I: experience of two British centres.

Authors:  A Vellodi; E P Young; A Cooper; J E Wraith; B Winchester; C Meaney; U Ramaswami; A Will
Journal:  Arch Dis Child       Date:  1997-02       Impact factor: 3.791

6.  Therapeutic neonatal hepatic gene therapy in mucopolysaccharidosis VII dogs.

Authors:  Katherine Parker Ponder; John R Melniczek; Lingfei Xu; Margaret A Weil; Thomas M O'Malley; Patricia A O'Donnell; Van W Knox; Gustavo D Aguirre; Hamutal Mazrier; N Matthew Ellinwood; Meg Sleeper; Albert M Maguire; Susan W Volk; Robert L Mango; Jean Zweigle; John H Wolfe; Mark E Haskins
Journal:  Proc Natl Acad Sci U S A       Date:  2002-09-13       Impact factor: 11.205

7.  Enzyme replacement in a canine model of Hurler syndrome.

Authors:  R M Shull; E D Kakkis; M F McEntee; S A Kania; A J Jonas; E F Neufeld
Journal:  Proc Natl Acad Sci U S A       Date:  1994-12-20       Impact factor: 11.205

Review 8.  Large animal models of neurological disorders for gene therapy.

Authors:  Christine Gagliardi; Bruce A Bunnell
Journal:  ILAR J       Date:  2009

9.  Radiographic evaluation of bones and joints in mucopolysaccharidosis I and VII dogs after neonatal gene therapy.

Authors:  Ramin Sedaghat Herati; Van W Knox; Patricia O'Donnell; Marina D'Angelo; Mark E Haskins; Katherine P Ponder
Journal:  Mol Genet Metab       Date:  2008-08-15       Impact factor: 4.797

10.  Five decades of progress in haematopoietic cell transplantation based on the preclinical canine model.

Authors:  M Lupu; R Storb
Journal:  Vet Comp Oncol       Date:  2007-03       Impact factor: 2.613

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.